Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
about
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.Role of Bruton's tyrosine kinase in B cells and malignancies.
P2860
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Use of anticoagulants and anti ...... d with single-agent ibrutinib.
@en
Use of anticoagulants and anti ...... d with single-agent ibrutinib.
@en-gb
type
label
Use of anticoagulants and anti ...... d with single-agent ibrutinib.
@en
Use of anticoagulants and anti ...... d with single-agent ibrutinib.
@en-gb
prefLabel
Use of anticoagulants and anti ...... d with single-agent ibrutinib.
@en
Use of anticoagulants and anti ...... d with single-agent ibrutinib.
@en-gb
P2093
P2860
P50
P356
P1476
Use of anticoagulants and anti ...... ed with single-agent ibrutinib
@en
P2093
Danelle F James
Jan A Burger
John C Byrd
Joi Ninomoto
Paul M Barr
Peter Hillmen
Richard R Furman
Stephen J Schuster
Steven Coutre
P2860
P304
P356
10.1111/BJH.14660
P407
P577
2017-04-10T00:00:00Z